Navidea Biopharmaceuticals, Inc. AMEX:NAVB

Navidea Biopharmaceuticals stock price today

$0.001
+0.00
+900%
Financial Health
0
1
2
3
4
5
6
7
8
9

Navidea Biopharmaceuticals stock price monthly change

-100.00%
month

Navidea Biopharmaceuticals stock price quarterly change

-100.00%
quarter

Navidea Biopharmaceuticals stock price yearly change

-100.00%
year

Navidea Biopharmaceuticals key metrics

Market Cap
10.00K
Enterprise value
6.37M
P/E
-0.44
EV/Sales
88.39
EV/EBITDA
-0.31
Price/Sales
108.23
Price/Book
-0.92
PEG ratio
N/A
EPS
-0.09
Revenue
N/A
EBITDA
-9.45M
Income
-2.53M
Revenue Q/Q
-100%
Revenue Y/Y
-99.05%
Profit margin
-32148.29%
Oper. margin
-27646.53%
Gross margin
96.66%
EBIT margin
-27646.53%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Navidea Biopharmaceuticals stock price history

Navidea Biopharmaceuticals stock forecast

Navidea Biopharmaceuticals financial statements

Navidea Biopharmaceuticals, Inc. (AMEX:NAVB): Profit margin
Dec 2022 610 -5.52M -905001.8%
Mar 2023 0 -793.48K
Jun 2023 0 6.03M
Sep 2023 0 -2.25M
Navidea Biopharmaceuticals, Inc. (AMEX:NAVB): Debt to assets
Dec 2022 4371606 12.51M 286.28%
Mar 2023 2367586 11.91M 503.26%
Jun 2023 8219812 9.00M 109.57%
Sep 2023 5698794 8.67M 152.29%
Navidea Biopharmaceuticals, Inc. (AMEX:NAVB): Cash Flow
Dec 2022 -2.43M -72.03K -99.76K
Mar 2023 -1.72M -39.40K -200.53K
Jun 2023 4.69M -65.00K 1.48M
Sep 2023 -10.24M -524.65K -188.57K

Navidea Biopharmaceuticals alternative data

Navidea Biopharmaceuticals, Inc. (AMEX:NAVB): Employee count
Aug 2023 11
Sep 2023 11
Oct 2023 11
Nov 2023 11
Dec 2023 11
Jan 2024 11
Feb 2024 11
Apr 2024 11
May 2024 11
Jun 2024 11
Jul 2024 11

Navidea Biopharmaceuticals other data

6.77% -12.39%
of NAVB is owned by hedge funds
577.09K -1.05M
shares is hold by hedge funds

Navidea Biopharmaceuticals, Inc. (AMEX:NAVB): Insider trades (number of shares)
Period Buy Sel
Aug 2022 5030 1740
Jun 2023 11969 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
SCOTT JOHN K JR. director, 10 percent owner:
Series J Convertible Preferred Stock 11,969 $0.1 $1,245
Purchase
WITTER MALCOLM G director
Warrant to Purchase Common Stock 230 $0.5 $115
Purchase
SCOTT JOHN K JR. director, 10 percent owner
Warrant to Purchase Common Stock 4,800 $0.5 $2,400
Sale
SCOTT JOHN K JR. director, 10 percent owner
Series F Redeemable Convertible Preferred Stock 1,740 $0.8 $1,392
Purchase
SCOTT JOHN K JR. director, 10 percent owner
Series F Redeemable Convertible Preferred Stock 1,740 $0.8 $1,392
Sale
SCOTT JOHN K JR. director, 10 percent owner
Series E Redeemable Convertible Preferred Stock 50,000 $2.3 $115,000
Purchase
SCOTT JOHN K JR. director, 10 percent owner
Series G Redeemable Preferred Stock 3,260 N/A N/A
Purchase
WITTER MALCOLM G director
Common Stock 20,000 $1.6 $31,960
Purchase
WITTER MALCOLM G director
Common Stock 15,000 $1.7 $25,470
Purchase
WITTER MALCOLM G director
Common Stock 10,000 $1.6 $16,000
Patent
Application
Filling date: 30 Dec 2021 Issue date: 30 Jun 2022
Grant
Filling date: 10 Oct 2017 Issue date: 28 Jun 2022
Application
Filling date: 8 Jul 2021 Issue date: 13 Jan 2022
Application
Filling date: 18 May 2021 Issue date: 4 Nov 2021
Application
Filling date: 30 Sep 2020 Issue date: 20 May 2021
Grant
Filling date: 10 Oct 2017 Issue date: 18 May 2021
Application
Filling date: 19 Aug 2020 Issue date: 25 Feb 2021
Application
Filling date: 27 Mar 2020 Issue date: 1 Oct 2020
Application
Filling date: 27 Jan 2020 Issue date: 30 Jul 2020
Wednesday, 3 July 2024
businesswire.com
Thursday, 20 June 2024
businesswire.com
Friday, 26 January 2024
businesswire.com
Friday, 1 December 2023
businesswire.com
Thursday, 5 October 2023
businesswire.com
businesswire.com
Thursday, 10 August 2023
businesswire.com
Monday, 31 July 2023
businesswire.com
InvestorPlace
Friday, 30 June 2023
Market Watch
Tuesday, 21 March 2023
Seeking Alpha
Tuesday, 15 November 2022
Seeking Alpha
Friday, 4 November 2022
Business Wire
Thursday, 8 September 2022
Seeking Alpha
Tuesday, 30 August 2022
Business Wire
Thursday, 12 May 2022
Seeking Alpha
Wednesday, 23 March 2022
Seeking Alpha
Thursday, 11 November 2021
Seeking Alpha
Thursday, 14 October 2021
Business Wire
Monday, 27 September 2021
Business Wire
Friday, 17 September 2021
Business Wire
  • What's the price of Navidea Biopharmaceuticals stock today?

    One share of Navidea Biopharmaceuticals stock can currently be purchased for approximately $0.

  • When is Navidea Biopharmaceuticals's next earnings date?

    Unfortunately, Navidea Biopharmaceuticals's (NAVB) next earnings date is currently unknown.

  • Does Navidea Biopharmaceuticals pay dividends?

    No, Navidea Biopharmaceuticals does not pay dividends.

  • How much money does Navidea Biopharmaceuticals make?

    Navidea Biopharmaceuticals has a market capitalization of 10.00K and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 87.65% to 65.65K US dollars.

  • What is Navidea Biopharmaceuticals's stock symbol?

    Navidea Biopharmaceuticals, Inc. is traded on the AMEX under the ticker symbol "NAVB".

  • What is Navidea Biopharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Navidea Biopharmaceuticals?

    Shares of Navidea Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Navidea Biopharmaceuticals's key executives?

    Navidea Biopharmaceuticals's management team includes the following people:

    • Dr. Michael Stanley Rosol Ph.D. Senior Vice President & Chief Medical Officer(age: 57, pay: $282,450)
  • How many employees does Navidea Biopharmaceuticals have?

    As Jul 2024, Navidea Biopharmaceuticals employs 11 workers.

  • When Navidea Biopharmaceuticals went public?

    Navidea Biopharmaceuticals, Inc. is publicly traded company for more then 32 years since IPO on 10 Nov 1992.

  • What is Navidea Biopharmaceuticals's official website?

    The official website for Navidea Biopharmaceuticals is navidea.com.

  • Where are Navidea Biopharmaceuticals's headquarters?

    Navidea Biopharmaceuticals is headquartered at 4995 Bradenton Avenue, Dublin, OH.

  • How can i contact Navidea Biopharmaceuticals?

    Navidea Biopharmaceuticals's mailing address is 4995 Bradenton Avenue, Dublin, OH and company can be reached via phone at +61 47937500.

Navidea Biopharmaceuticals company profile:

Navidea Biopharmaceuticals, Inc.

navidea.com
Exchange:

AMEX

Full time employees:

11

Industry:

Biotechnology

Sector:

Healthcare

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

4995 Bradenton Avenue
Dublin, OH 43017-3552

CIK: 0000810509
ISIN: US63937X2027
CUSIP: 63937X202